Your browser doesn't support javascript.
loading
Myosin Vb as a tumor suppressor gene in intestinal cancer.
Cartón-García, Fernando; Brotons, Bruno; Anguita, Estefanía; Dopeso, Higinio; Tarragona, Jordi; Nieto, Rocio; García-Vidal, Elia; Macaya, Irati; Zagyva, Zsuzsanna; Dalmau, Mariona; Sánchez-Martín, Manuel; van Ijzendoorn, Sven C D; Landolfi, Stefania; Hernandez-Losa, Javier; Schwartz, Simo; Matias-Guiu, Xavier; Ramón Y Cajal, Santiago; Martínez-Barriocanal, Águeda; Arango, Diego.
Affiliation
  • Cartón-García F; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Brotons B; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Anguita E; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain.
  • Dopeso H; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Tarragona J; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain.
  • Nieto R; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • García-Vidal E; Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, Lleida, Spain.
  • Macaya I; Group of Oncological Pathology, Institut de Recerca Biomedica de Lleida (IRBLleida), Lleida, Spain.
  • Zagyva Z; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Dalmau M; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Sánchez-Martín M; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • van Ijzendoorn SCD; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Landolfi S; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Hernandez-Losa J; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), Lleida, Spain.
  • Schwartz S; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
  • Matias-Guiu X; Servicio de Transgénesis, Nucleus, Universidad de Salamanca, Salamanca, Spain.
  • Ramón Y Cajal S; Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.
  • Martínez-Barriocanal Á; Department of Biomedical Sciences of Cells and Systems, Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Arango D; Translational Molecular Pathology, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Oncogene ; 41(49): 5279-5288, 2022 12.
Article in En | MEDLINE | ID: mdl-36316444
ABSTRACT
Colorectal cancer causes >900,000 deaths every year and a deeper understanding of the molecular mechanisms underlying this disease will contribute to improve its clinical management and survival. Myosin Vb (MYO5B) regulates intracellular vesicle trafficking, and inactivation of this myosin disrupts the polarization and differentiation of intestinal epithelial cells causing microvillous inclusion disease (MVID), a rare congenital disorder characterized by intractable life-threatening diarrhea. Here, we show that the loss Myosin Vb interfered with the differentiation/polarization of colorectal cancer cells. Although modulation of Myosin Vb expression did not affect the proliferation of colon cancer cells, MYO5B inactivation increased their migration, invasion, and metastatic potential. Moreover, Myo5b inactivation in an intestine-specific knockout mouse model caused a >15-fold increase in the number of azoxymethane-initiated small intestinal tumors. Consistently, reduced expression of Myosin Vb in a cohort of 155 primary colorectal tumors was associated with shorter patient survival. In conclusion, we show here that loss of Myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Moreover, reduced expression of Myosin Vb in primary tumors identifies a subset of poor prognosis colorectal cancer patients that could benefit from more aggressive therapeutic regimens.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms / Myosin Type V Limits: Animals / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Colonic Neoplasms / Myosin Type V Limits: Animals / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Spain